TABLE OF CONTENTS

Volume 64, Issue 1 (July 1998)

Top

Commentary

Expectations and the placebo effect in clinical drug trials: Why we should not turn a blind eye to unblinding, and other cautionary notes

Leora C. Swartzman PhD and Jacquelyn Burkell PhD

Clin Pharmacol Ther 64: 1-7; doi:10.1016/S0009-9236(98)90016-9

Top

Pharmacokinetics and Drug Disposition

Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6

Adedayo Adedoyin PhD, Patricia A. Arns MD, W.O. Richards MD, Grant R. Wilkinson PhD and Robert A. Branch MD

Clin Pharmacol Ther 64: 8-17; doi:10.1016/S0009-9236(98)90017-0

Time course of enzyme induction in humans: Effect of pentobarbital on nortriptyline metabolism

Christer von Bahr MD, PhD, Eugen Steiner MD, PhD, Yuichi Koike MD, PhD and Johan Gabrielsson PhD

Clin Pharmacol Ther 64: 18-26; doi:10.1016/S0009-9236(98)90018-2

Pharmacokinetics of intravenous dynorphin A(1–13) in opioid-naive and opioid-treated human volunteers

Pedro L. Gambús MD, Thomas W. Schnider MD, Charles F. Minto MBChB, Elizabeth J. Youngs MD, Valerie Billard MD, William G. Brose MD, Günther Hochhaus PhD and Steven L. Shafer MD

Clin Pharmacol Ther 64: 27-38; doi:10.1016/S0009-9236(98)90019-4

Single-dose disulfiram does not inhibit CYP2A6 activity

Evan D. Kharasch MD, PhD, Douglas C. Hankins MA, Pamela J. Baxter PhD and Kenneth E. Thummel PhD

Clin Pharmacol Ther 64: 39-45; doi:10.1016/S0009-9236(98)90020-0

Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans

Thrina Loennechen PhD, Charles R. Yates PharmD, Michael Y. Fessing PhD, Mary V. Relling PharmD, Eugene Y. Krynetski PhD and William E. Evans PharmD

Clin Pharmacol Ther 64: 46-51; doi:10.1016/S0009-9236(98)90021-2

Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers

Chin B. Eap PhD, Christiane Schnyder MD, Jaques Besson MD, Line Savary and Thierry Buclin MD

Clin Pharmacol Ther 64: 52-57; doi:10.1016/S0009-9236(98)90022-4

Effect of itraconazole on the pharmacokinetics of atorvastatin

Teemu Kantola MB, Kari T. Kivistö MD and Pertti J. Neuvonen MD

Clin Pharmacol Ther 64: 58-65; doi:10.1016/S0009-9236(98)90023-6

Disposition and immunodynamics of basiliximab in liver allograft recipients

John Kovarik PharmD, Thomas Breidenbach PhD, Christophe Gerbeau PhD, Alex Korn PhD, Albrecht-Georg Schmidt MD and Björn Nashan MD

Clin Pharmacol Ther 64: 66-72; doi:10.1016/S0009-9236(98)90024-8

Top

Pharmacodynamics and Drug Action

Metabolism and action of urodilatin infusion in healthy volunteers

Jan Carstens MD, Kaare T. Jensen MD and Erling B. Pedersen MD, DMSc

Clin Pharmacol Ther 64: 73-86; doi:10.1016/S0009-9236(98)90025-X

Dose-related cardiovascular and endocrine effects of transdermal nicotine

Shoshana Zevin MD, Peyton Jacob III PhD and Neal L. Benowitz MD

Clin Pharmacol Ther 64: 87-95; doi:10.1016/S0009-9236(98)90026-1

Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension

Anne Lafleche MD, Sylvie Gautier MD, Jirar Topouchian MD, Catherine S. Wilmet MD, Xavier Girerd MD, Michel E. Safar MD and Athanase Benetos MD

Clin Pharmacol Ther 64: 96-105; doi:10.1016/S0009-9236(98)90027-3

Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone

Iñaki F. Trocóniz PhD, Tarja H. Naukkarinen MSc, Hanna M. Ruottinen MD, Urpo K. Rinne MD, Ariel Gordin MD and Mats O. Karlsson PhD

Clin Pharmacol Ther 64: 106-116; doi:10.1016/S0009-9236(98)90028-5

Cerebrospinal fluid prostaglandins after systemic dipyrone intake

Micha Levy MD, Kay Brune MD, Ester Zylber-Katz PhD, Oren Cohen MD, Yoseph Caraco MD and Gerd Geisslinger PhD, MD

Clin Pharmacol Ther 64: 117-122; doi:10.1016/S0009-9236(98)90029-7

Top

Clinical Pharmacology Rounds

Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein

Hiroko Wakasugi MS, Ikuko Yano PhD, Tatsuya Ito MS, Tohru Hashida BS, Takahiro Futami PhD, Ryuji Nohara MD, Shigetake Sasayama MD and Ken-ichi Inui PhD

Clin Pharmacol Ther 64: 123-128; doi:10.1016/S0009-9236(98)90030-3

Top

Letters to the Editor

CYP3A4 and the erythromycin breath test

David Wagner PhD

Clin Pharmacol Ther 64: 129; doi:10.1016/S0009-9236(98)90031-5

Reply

David E. Smith PhD

Clin Pharmacol Ther 64: 130; doi:10.1016/S0009-9236(98)90032-7

Top

USAN Council

List No. 406 New Names

Clin Pharmacol Ther 64: 131-132; doi:10.1016/S0009-9236(98)90033-9

Extra navigation

.
ADVERTISEMENT